| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 16 |
| 1 | PREDNISOLONE | 12 |
| 2 | PREDNISOLONE ORAL | 12 |
| 3 | PREDNISOLONE ORAL SOLUTION | 12 |
| 4 | DEXAMETHASONE | 11 |
| 5 | DEXAMETHASONE 1.5 MG | 11 |
| 6 | CYCLOPHOSPHAMIDE | 9 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 9 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 9 |
| 9 | DARATUMUMAB | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | COAGULATION FACTOR VIIA RECOMBINANT HUMAN | 1 | 0.0108 |
| 1 | REVUMENIB | 2 | 0.0019 |
| 2 | CEDAZURIDINE AND DECITABINE | 1 | 0.0010 |
| 3 | MESNA INJECTION | 7 | 0.0008 |
| 4 | MESNA | 7 | 0.0008 |
| 5 | CASPOFUNGIN ACETATE | 1 | 0.0006 |
| 6 | PERFLUOROHEXYLOCTANE | 1 | 0.0004 |
| 7 | PENICILLIN V POTASSIUM | 1 | 0.0004 |
| 8 | COAGULATION FACTOR VIIA (RECOMBINANT) | 1 | 0.0004 |
| 9 | CILTACABTAGENE AUTOLEUCEL | 2 | 0.0003 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 20 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 16 |
| 2 | Alkylating Drug [EPC] | 9 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 9 |
| 4 | Thalidomide Analog [EPC] | 9 |
| 5 | Proteasome Inhibitor [EPC] | 8 |
| 6 | Kinase Inhibitor [EPC] | 7 |
| 7 | Leukocyte Growth Factor [EPC] | 7 |
| 8 | Topoisomerase Inhibitor [EPC] | 7 |
| 9 | Complement Inhibitor [EPC] | 6 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Semifluorinated Alkane [EPC] | 1 | 0.0004 |
| 1 | CD52-directed Cytolytic Antibody [EPC] | 4 | 0.0002 |
| 2 | Complement Inhibitor [EPC] | 6 | 0.0001 |
| 3 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 1 | 0.0001 |
| 4 | Thyroid Hormone Synthesis Inhibitor [EPC] | 1 | 0.0001 |
| 5 | Topoisomerase Inhibitor [EPC] | 7 | 0.0001 |
| 6 | Bile Acid Sequestrant [EPC] | 1 | 0.0001 |
| 7 | Proteasome Inhibitor [EPC] | 8 | 0.0001 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 16 | 0.0001 |
| 9 | Leukocyte Growth Factor [EPC] | 7 | 0.0000 |